![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-8324
Source: Inpharma, Vol.1, Iss.1430, 2004-01, pp. : 13-13
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Phase II Trial of Temozolomide in Patients with Cisplatin-Refractory Germ Cell Tumors
By Varuni Kondagunta G. Bacik Jennifer Schwartz Lawrence Sheinfeld Joel Bajorin Dean Vuky Jacqueline Marion Stephanie Mazumdar Madhu Bosl George J. Motzer Robert J.
Investigational New Drugs, Vol. 22, Iss. 2, 2004-04 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Docetaxel plus gemcitabine shows antitumour efficacy in patients with advanced NSCLC
Inpharma, Vol. 1, Iss. 1280, 2001-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Gemcitabine plus cisplatin for NSCLC
Inpharma, Vol. 1, Iss. 1222, 2000-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
New prospects for the treatment of germ-cell tumours
Expert Opinion on Investigational Drugs, Vol. 7, Iss. 7, 1998-07 ,pp. :